Group 1 - Baxter International Inc. announced the appointment of Andrew Hider as President and CEO, effective no later than September 3, 2025 [1] - Brent Shafer, who has served as Chairman and interim CEO since February 2025, will transition to the role of independent Chairman of the Board [1] Group 2 - Andrew Hider has 25 years of cross-industry experience and a global perspective, focusing on growth-oriented and people-centric leadership [2] - Hider served as CEO and Director of ATS, a leading automation solutions provider, where he significantly improved profit margins and nearly doubled adjusted revenue over five years with a compound annual growth rate (CAGR) in the low double digits [4][5] - Under Hider's leadership, ATS's stock price more than doubled since 2017, outperforming major indices [5] Group 3 - Baxter International, founded in 1931 and headquartered in Deerfield, Illinois, specializes in medical products for chronic and critical care, developing and selling products for complex conditions such as hemophilia and cancer [6] - Baxter's diverse business integrates medical devices, pharmaceuticals, and biotechnology, with a leading position in home kidney therapy and recombinant factor products for bleeding disorders [6] - The company employs approximately 38,000 members globally [6]